<DOC>
	<DOCNO>NCT01803295</DOCNO>
	<brief_summary>In propose study investigator aim evaluate effect standard care dose ( 40mg ) MMC mixed TC-3 gel ( sustained release mechanism drug ) low risk recurrent NMIBC lesion compare finding instillation standard mode instillation- 40mg MMC water order examine hypothesis MMC mix TC-3 gel least non-inferior even superior result standard instillation mode The investigator believe study importance several aspect : 1 . It evaluate new mode bladder instillation may bypass drawback current instillation mode . 2 . If prove effective mode treatment might save need TURBT performance serve new mode tumor ablation . 3 . Even prove partially effective mode treatment diminish tumor size number thus enable limited TURBT procedure . 4 . This mode treatment enable immediate medical attendance patient 's tumor recurrence without wait period ( result queues medical center ) TURBT , might improve patient 's prognostic outcome . 5 . If experimental treatment prove well ablative effect , could translate well prophylactic effect tumor recurrence .</brief_summary>
	<brief_title>Pre-TURBT TC-3 Gel Intravesical Instillation NMIBC</brief_title>
	<detailed_description>Non-muscle-Invasive Bladder cancer mainly treat tumor resection ( Trans Urethral Resection - TUR ) , follow series intravesical instillation prophylactic chemotherapeutic drug Mitomycin C ( MMC ) BCG . This treatment approach limit due rapid dilution chemotheraputic drug incoming urine clearance urination . TheraCoat core technology base reverse thermal biodegradable gel ( TC-3 ) ( low viscosity 5°C gel appearance body temperature ) drug retention urinary bladder . Prior instillation , TC-3 hydrogel , liquid state , mixed MMC.TC-3 mixed MMC instill bladder catheter . Following gel insertion bladder , gel solidifies form drug reservoir inside bladder . Upon contact urine gel dissolve clear bladder . Intravesical MMC instillation use TheraCoat gel expect increase treatment efficiency due prolongation treatment duration consequently improve bladder exposure MMC . Treatment Protocol - Immediately follow baseline cystoscopy tumor diagnosis patient undergo 6 weekly instillation follow 2-4 week heal period . 1st Follow-Up Visit ( Pre-Scheduled TURBT Visit ) : The patient undergo second Cystoscopy compare Baseline status follow-up period : 3,6,9,12 month .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>1 . Patient 21 year age old . 2 . Patient sign Informed Consent Form willing able abide protocol . 3 . Naïve recurrent low grade ( LG ) NMIBC tumor 4 . Recurrent patient Single multiple tumor 5 . Naive patient 2 tumor 6 . No prior history HG and/or T1 past 5 year . 7 . No prior history Tis 8 . At least one Tumor ≥ 1 mm evaluate visually investigator . 9 . Largest tumor diameter ≤ 30 mm evaluate visually investigator 10 . Cystoscopic appearance papillary Low grade tumor 11 . No active urinary tract infection confirm urine culture 12 . If patient female childbearing potential , use two acceptable &amp; effective method contraception , 6 month post treatment 13 . If patient male use condom intercourse , least 48 hour post instillation 14 . If patient male partner female childbearing potential , advise use two acceptable &amp; effective method contraception 6 month post treatment . 1 . Carcinoma In Situ ( CIS ) . 2 . `` High Grade '' urine cytology conclusive HG . 3 . `` High Grade '' tumor result cold cup biopsy . 4 . Tumor locate prostatic urethra . 5 . Previous systemic chemotherapy last 2 year pelvic radiotherapy . 6 . Pregnant breastfeeding patient . 7 . Previous treatment BCG within last 12 month . 8 . The patient least 3 month cystoscopically confirm tumorfree interval last TURBT current tumor recurrence . 9 . Treatment full course intravesical chemotherapy within 3 last month . 10 . The patient has/had bladder tumor histology TCC . 11 . Known contraindication hypersensitivity MMC gel . 12 . The patient known history upper urinary tract urothelial carcinoma , Renal Cell carcinoma renal cancer . 13 . The patient know urinary retention , accord investigator 's opinion , might lead avoid patient receive treatment . 14 . The patient bleed disorder screen platelet count &lt; 50X109/L . 15 . The patient screen hemoglobin &lt; 10 mg/dL . 16 . The patient condition concurrent severe and/or uncontrolled medical psychiatric disease ( e.g . uncontrolled diabetes , compensate congestive heart failure ( NYHA III ) , myocardial infarction within 6 month study , unstable uncontrolled hypertension active uncontrolled infection ) , could compromise participation , compliance schedule visit and/or completion . 17 . The patient participate investigational interventional study within past 90 day . 18 . The patient document sever vesicoureteral reflux indwell ureteral stent . 19 . The patient tumor bladder diverticulum . 20 . The patient participate prior TheraCoat 's trial MMC TC3</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Non Muscle Invasive Bladder Cancer</keyword>
	<keyword>Intravesical instillation</keyword>
	<keyword>Mitomycin C</keyword>
	<keyword>Hydrogel Reverse thermal gelation</keyword>
	<keyword>Drug retention</keyword>
	<keyword>Urinary Bladder Neoplasms</keyword>
	<keyword>Urologic Neoplasms</keyword>
	<keyword>Urinary Bladder Diseases</keyword>
	<keyword>Urologic Diseases</keyword>
	<keyword>Mitomycin</keyword>
</DOC>